Fundraising Fox

LabGenius

London · United Kingdom corporation · 16 known investors

labgeni.us ↗

LabGenius develops EVA, an automated discovery engine for identifying and co-optimizing complex therapeutic antibodies such as multispecifics across multiple properties. Its internal pipeline focuses on selectivity-enhanced antibodies for treating solid tumours.

AI & Machine LearningBiotechDeep Techin /labgeniustx@labgeni_us

Founders & leadership

HR
Harrison RickerbyNamed on SEC filing

Board

JF
James FieldBoard directorFounder at Octopus Ventures

Investors · 16

Acequia Capital (AceCap)Seattle · $100K – $5M
Air Street CapitalSt. Peter Port · $500K – $10M
BackedLondon · $500K – $5M
Beast VenturesHong Kong
Champion Hill Ventures$500K – $1M
GigafundAustin · $1M – $5M
Kindred CapitalLondon
M VenturesLos Angeles · $10.8M
Obvious VenturesSan Francisco · $250K – $6M
Octopus VenturesLondon · $130K – $1.3M
Recode VenturesSan Franciscovia Armen A. Vidian · inferred
AtomicoreportedLondon
Berggruen HoldingsreportedLos Angeles · $200M
Kindred CapitalreportedNorwalk
Lux CapitalreportedNew York · $100K – $100M
System.Onereported

Reported raises · per SEC filings

Form D private placements

$2.8M disclosed across 1 round · 2017

▶$2.8MraisedOct 2017 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James FieldExecutive Officer, Director
  • Harrison RickerbyExecutive Officer, Director
Offering amount
$2.8M
Amount sold
$2.8M
First sale
Oct 2017
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

LabGenius Raises £35 Million - European Pharmaceutical Manufacturerpharmaceuticalmanufacturer.media · May 2024London-based LabGenius raises over €40.1 million to further develop its ML-driven antibody discovery platform | EU-Startupseu-startups.com · May 2024Press release | LabGenius raises £35 million led by M Ventures to further develop its ML-driven antibody discovery platform and progress a pipeline of assets towards the clinic | LabGenius Therapeuticslabgeniustx.com · May 2024This London-based startup uses AI and robotics to discover protein therapeutics; raises €12.8M - Silicon Canalssiliconcanals.com · Oct 2020LabGenius Raises $10M in Series A Funding - FinSMEsfinsmes.com · Oct 2019LabGenius Raises $3.66M in Seed Funding - FinSMEsfinsmes.com · Nov 2017

Frequently asked questions

What does LabGenius do?
LabGenius develops EVA, an automated discovery engine for identifying and co-optimizing complex therapeutic antibodies such as multispecifics across multiple properties. Its internal pipeline focuses on selectivity-enhanced antibodies for treating solid tumours.
Who are LabGenius's investors?
LabGenius's investors include Acequia Capital (AceCap), Air Street Capital, Backed, Beast Ventures, Champion Hill Ventures, Gigafund, Kindred Capital, M Ventures and 8 more.
How much funding has LabGenius raised?
LabGenius has disclosed $2.8M raised across 1 round.
Where is LabGenius headquartered?
LabGenius is headquartered in London.